RADX (Radiopharm Theranostics Limited American Depositary Shares) Stock Analysis - Hedge Fund Holdings

Radiopharm Theranostics Limited American Depositary Shares (RADX) is a publicly traded Healthcare sector company. As of May 21, 2026, RADX trades at $4.58 with a market cap of $37.45M and a P/E ratio of 0.00. RADX moved -0.22% today. Year to date, RADX is -10.20%; over the trailing twelve months it is +4.09%. Its 52-week range spans $3.50 to $50.82. Analyst consensus is buy with an average price target of $22.50. Rallies surfaces RADX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns RADX stock?

Rallies tracks hedge fund and 13F ownership for RADX, including fund holders, share counts, and position changes when data is available.

RADX Key Metrics

Key financial metrics for RADX
MetricValue
Price$4.58
Market Cap$37.45M
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$50.82
52-Week Low$3.50
Volume12
Avg Volume0
Revenue (TTM)$0
Net Income$0
Gross Margin0.00%

Latest RADX News

RADX Analyst Consensus

2 analysts cover RADX: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $22.50.

Common questions about RADX

Who owns RADX stock?
Rallies tracks hedge fund and 13F ownership for RADX, including fund holders, share counts, and position changes when data is available.
Does Rallies show 13F holders for RADX?
Yes. Rallies tracks hedge fund and 13F ownership data for RADX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is RADX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for RADX. It does not provide personalized investment advice.
RADX

RADX